An open-label international multicentric phase II study of nilotinib in progressive pigmented villo-nodular synovitis (PVNS) not amenable to a conservative surgical treatment.

An open-label international multicentric phase II study of nilotinib in progressive pigmented villo-nodular synovitis (PVNS) not amenable to a conservative surgical treatment.

Show other versions (1)

Bibliographic Details
Main Authors:	Gelderblom, H, Perol, D, Chevreau, C, Tattersall, M, Stacchiotti, S, Casali, P, Cropet, C, Piperno-Neumann, S, Le Cesne, A, Italiano, A, Ferraresi, V, Duffaud, F, Penel, N, Dileo, P, Bertucci, F, Hassan, A, Kroep, JR, Denizot-Guillemaut, S, Blay, J
Format:	Journal article
Published:	2013

Similar Items

An open-label international multicentric phase II study of nilotinib in progressive pigmented villo-nodular synovitis (PVNS) not amenable to a conservative surgical treatment
by: Ray-Coquard, I, et al.
Published: (2012)

Localized pigmented villo-nodular synovitis of trochanteric bursa
by: Bruns, Juergen, et al.
Published: (2023-10-01)

Pigmented Villo-Nodular Synovitis of Shoulder Joint Leading to Humeral Head Erosion
by: Alok Chandra Agrawal, et al.
Published: (2020-01-01)

Systematic review: total knee arthroplasty (TKA) in patients with pigmented villonodular synovitis (PVNS)
by: Yi Chuen Tan, et al.
Published: (2021-02-01)

Pigmented villonodular synovitis (PVNS) of the knee mimicking septic arthritis in a paediatric patient: A case report
by: Indra F, et al.
Published: (2021)

Pigmented Villonodular Synovitis (PVNS) of the Knee mimicking Septic Arthritis in a Paediatric Patient: A Case Report
by: Indra F, et al.
Published: (2021-11-01)

The causes of unsatisfactory results and mistakes in treatment of patients with pigmented villo-nodular synovitis (teno-synovial giant-cell tumor) of a knee joint
by: Yu. O. Kostogryz, et al.
Published: (2020-05-01)

PVNS or pseudo aneurysm: MRI-problem solving or misleading?
by: Bhagya Sannananja, et al.
Published: (2015-01-01)

Recent advances in managing gastrointestinal stromal tumor [version 1; referees: 2 approved]
by: Florence Duffaud, et al.
Published: (2017-09-01)

Desmoid type fibromatosis in pediatric and young adults from French databases: Clinical characteristics and initial outcome according to age
by: Séverine Bouttefroy, et al.
Published: (2023-01-01)

Nilotinib-Associated Destructive Thyroiditis
by: Suhalia Bakerywala, et al.
Published: (2015-01-01)

Nilotinib-Induced Keratosis Pilaris
by: Wai Mun Sean Leong, et al.
Published: (2016-04-01)

Nilotinib after imatinib failure
by: Luca Pezzullo
Published: (2015-10-01)

Use of nilotinib in the diabetic patient
by: Carmen Tomaselli
Published: (2015-10-01)

Complete molecular response induced by nilotinib in a patient previously treated with imatinib, nilotinib and dasatinib
by: Giuseppe Pietrantuono
Published: (2015-10-01)

Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
by: Yoo Jin Na, et al.
Published: (2021-03-01)

The role of a magnet-resonance tomography in diagnosis of a teno-synovial giant-cell tumor (the pigment villo-nodular synoviitis) of a knee joint
by: Yu. O. Kostogryz, et al.
Published: (2019-12-01)

Immunophenotypic distinction between pigmented villonodular synovitis and haemosiderotic synovitis.
by: Mahendra, G, et al.
Published: (2010)

Nilotinib: Disrupting the MYC-MAX Heterocomplex
by: Kamilla Shah MS, et al.
Published: (2024-07-01)

Clinical cardiac safety profile of nilotinib
by: Theo D. Kim, et al.
Published: (2012-06-01)

Nilotinib therapy after resistance to imatinib
by: Raffaele Porrini, et al.
Published: (2015-10-01)

Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide study
by: Emmanuelle Bompas, et al.
Published: (2018-08-01)

S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL.
by: Andreas Hochhaus, et al.
Published: (2023-08-01)

A Rare Case Report of Fungal Synovitis Presenting as Pigmented Villonodular Synovitis
by: Banyameen Iqbal, et al.
Published: (2024-08-01)

One year of experience with nilotinib: the nurse perspective
by: Watts, A, et al.
Published: (2013)

Nilotinib - new step of success in CML therapy
by: E. G. Lomaia, et al.
Published: (2022-11-01)

Extending the reach of nilotinib in chronic myeloid leukemia
by: Michael J. Mauro
Published: (2014-07-01)

EFFICACY OF NILOTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
by: Sajid Ali, et al.
Published: (2019-12-01)

Spotlight on nilotinib in the treatment of chronic myelogenous leukemia
by: Harnicar S, et al.
Published: (2014-08-01)

EFFICACY OF NILOTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
by: Sajid Ali, et al.
Published: (2019-12-01)

Effects of nilotinib on regulatory T cells: the dose matters
by: Chen Baoan, et al.
Published: (2010-01-01)

Nilotinib efficacy in a patient resistant to imatinib
by: Luigia Luciano
Published: (2015-10-01)

Pigmented villonodular synovitis of the midfoot
by: P Sierens, et al.
Published: (2010-04-01)

Is painless synovitis different from painful synovitis? A controlled, ultrasound, radiographic, clinical trial
by: Daniele Freitas Pereira, et al.

Development and targeted use of nilotinib in chronic myeloid leukemia
by: Carmen Fava, et al.
Published: (2008-11-01)

Thyroid dysfunction in chronic myeloid leukemia patients on nilotinib
by: Khaleed J Khaleel, et al.
Published: (2018-01-01)

Nilotinib in Chronic Myeloid Leukemia: a comprehensive approach
by: Mario Annunziata
Published: (2015-10-01)

Safety and efficacy of nilotinib after 10 years of interferon
by: Filippo Russo
Published: (2015-10-01)

Nilotinib and Imatinib Utilization in Iran over 14 years
by: Ava Mansouri, et al.
Published: (2020-12-01)

The use of nilotinib in clinical practice: monitoring effectiveness and tolerability
by: Giorgina Specchia
Published: (2015-10-01)